Hamilton Depression Rating Scale Calculator (HAM-D 17)

How to Use This Calculator

1. Rate all 17 items based on your structured clinical interview.
2. Total HAM-D score and severity classification appear instantly.
3. Core Symptoms tab: key depressive items with suicide alert.
4. Sleep Profile tab: insomnia pattern analysis.
5. Professional tier: full remission tracking, melancholic feature detection, and treatment recommendation.

Formula

Example

Frequently Asked Questions

• What is the HAM-D and how was it developed? ▼
  The Hamilton Rating Scale for Depression (HAM-D or HRSD) was developed by Max Hamilton and first published in the Journal of Neurology, Neurosurgery and Psychiatry in 1960. It was the first standardized rating scale for depression and remains the most widely used clinician-administered depression severity measure in pharmaceutical trials and academic research. The original scale had 17 primary items plus 4 additional items used for research purposes (the 21-item version). This calculator implements the standard 17-item version (HAM-D 17), which is universally used in regulatory submissions for antidepressant approval. Items are rated by a trained clinician based on a structured or semi-structured interview — the scale is NOT self-administered, which distinguishes it from the PHQ-9. Each item is rated on either a 3-point (0–2) or 5-point (0–4) scale depending on the symptom. The maximum score is 52 points. Unlike the PHQ-9, which maps to DSM criteria, the HAM-D was developed empirically from clinical observation and includes neurovegetative items (sleep, appetite, weight, psychomotor changes, sexual function) that are particularly sensitive to biological aspects of depression and to antidepressant drug effects, making it the preferred outcome measure for clinical trials.
• How are HAM-D 17 scores interpreted for depression severity? ▼
  The HAM-D 17 severity bands have been established through decades of clinical use and regulatory guidance from the FDA and EMA. Scores of 0–7 are considered normal or in remission — this range is the standard remission criterion used in clinical trials and is the target of all pharmacological treatment. Scores of 8–13 indicate mild depression — patients at this level have clinically relevant but not severe symptoms; pharmacotherapy trials often require a score of at least 18 at baseline to include patients in efficacy studies. Scores of 14–18 indicate moderate depression, representing the minimum severity for most antidepressant trial inclusion criteria. Scores of 19–22 represent severe depression requiring active treatment intensification. Scores above 22 indicate very severe depression with high risk of complications including psychiatric hospitalization; electroconvulsive therapy (ECT) should be considered for patients who have not responded to adequate pharmacotherapy at this severity. Response in clinical trials is universally defined as a ≥50% reduction from baseline score; remission is defined as a score of ≤7. These endpoints remain standard in FDA regulatory submissions for new antidepressant approvals.
• How does the HAM-D differ from self-report scales like PHQ-9? ▼
  The HAM-D and PHQ-9 measure related but distinct constructs and serve different clinical purposes. The PHQ-9 is self-administered (patient-rated) and maps directly to DSM-5 diagnostic criteria for major depressive disorder — it is optimized for screening and monitoring in primary care. The HAM-D is clinician-rated based on a structured or semi-structured interview and reflects the clinician's assessment of observable signs and reported symptoms. This distinction has important implications. The HAM-D includes items for observable psychomotor retardation and agitation that patients may not accurately self-report. It includes neurovegetative items (weight loss, genital symptoms) that are particularly sensitive to biological antidepressant effects. Items for insight and hypochondriasis detect aspects of depression important for treatment planning but not captured in the PHQ-9. The HAM-D requires approximately 20–30 minutes of clinician time, limiting its use in routine primary care but making it ideal for clinical trials and specialty settings. Direct score comparisons between HAM-D and PHQ-9 are not possible due to different item weights and response formats, though approximate crosswalks exist — a PHQ-9 score of 10 approximately corresponds to a HAM-D-17 score of 14 in population studies. For clinical monitoring in primary care, the PHQ-9 is preferred; for research and specialist assessment, the HAM-D is the gold standard.
• What are melancholic features and how does the HAM-D detect them? ▼
  Melancholia is a clinically and biologically distinct subtype of major depressive disorder characterized by severe biological disturbances and specific symptom patterns that predict preferential response to biological treatments. The HAM-D 17 is particularly sensitive to melancholic features because it emphasizes neurovegetative and psychomotor items. Key melancholic features captured by the HAM-D include: early morning awakening (item 6 — late insomnia, scored 0–2), with the score reflecting waking 2 or more hours before the usual time; diurnal variation of mood (mood worse in the morning — not a scored HAM-D item but noted during interview); psychomotor retardation (item 8, 0–4) or agitation (item 9, 0–4); significant weight loss (item 16); loss of interest in previously pleasurable activities captured through work and activities item (item 7); and feelings of guilt disproportionate to circumstances (item 2). Patients with melancholic depression generally have higher HAM-D scores at comparable PHQ-9 levels because the biological items dominate. Melancholic features predict better response to tricyclic antidepressants and ECT compared to non-melancholic depression and may respond less robustly to psychotherapy alone. Recognition of melancholic features using the HAM-D informs the treatment algorithm by supporting biological intervention as the cornerstone of management.
• How is the HAM-D used in clinical antidepressant trials? ▼
  The HAM-D 17 is the universal primary efficacy endpoint in regulatory antidepressant trials and has been used in virtually every FDA and EMA antidepressant approval since the 1960s. Regulatory submissions require demonstration of statistically and clinically significant HAM-D reduction versus placebo, with the primary endpoint typically being mean change from baseline HAM-D-17 total score at week 6 or 8. Minimum efficacy thresholds require a drug-placebo difference of at least 3 points on the HAM-D, though clinical meaningfulness requires at least 7–9 points improvement. Entry criteria for typical antidepressant trials require a baseline HAM-D score of ≥18–20 (moderate-to-severe depression) to ensure adequate room for measurable improvement. Response (≥50% reduction) and remission (score ≤7) are secondary endpoints that determine whether regulatory language about "remission" or "response" can be included in prescribing information. The STAR*D trial, the largest antidepressant effectiveness study ever conducted, used the Quick Inventory of Depressive Symptomatology (QIDS) as its primary measure rather than HAM-D for cost and practicality reasons, but cross-validated findings against HAM-D. Modern regulatory guidance acknowledges that patient-reported outcomes should supplement clinician-rated scales, but the HAM-D remains the required primary endpoint for most regulatory submissions.

Related Calculators